Advertisement

European Journal of Clinical Pharmacology

, Volume 75, Issue 1, pp 109–117 | Cite as

Twelve-year trend in the use of zolpidem and physicians’ non-compliance with recommended duration: a Korean national health insurance database study

  • Yunjeung Jang
  • Inmyung Song
  • In-Sun Oh
  • Ju-Young ShinEmail author
Pharmacoepidemiology and Prescription

Abstract

Objectives

Abuse of zolpidem has sporadically been reported and little is known regarding nationwide patterns of zolpidem use in Korea. This study investigates the extent of zolpidem usage exceeding the recommended duration and the predictors.

Methods

We conducted a drug utilization study using the national sample cohort database of the Korea National Health Insurance Corporation between 2002 and 2013. The study subjects were patients treated with zolpidem in the outpatient setting. An episode was defined as a period of continuous zolpidem therapy. The provider-based episode allowed for a gap of up to 3 days between two consecutive prescriptions from the same institution. The person-based episode allowed for a gap of up to 3 days, regardless of institution. We calculated the proportion of zolpidem use for periods over 30 days and conducted logistic regression analyses to investigate the relevant predictors. An adjusted odds ratio (aOR) with a 95% confidence interval (CI) was estimated for each predictor.

Results

The usage of zolpidem is dramatically increased by approximately 18 times since zolpidem was authorized in the market (1181 in 2002 vs. 21,399 in 2013). The treatment duration in 8.3% of episodes exceeded 30 days out of 75,087 zolpidem users. The odds of zolpidem prescription exceeding 30 days were highest in patients aged 65 years and older (aOR = 2.13, 95% CI 1.78–2.53) and at tertiary hospitals (aOR = 2.14, 95% CI 1.68–2.72). Women were more likely than men to be treated with zolpidem for over 30 days.

Conclusion

We found dramatic increase of zolpidem use from 2002 to 2013. In 8.3% of the prescribed episodes of zolpidem, the recommended duration was exceeded. Efforts are required to reduce prescriptions that are inconsistent with the recommended guidelines for older patients, women, and in tertiary hospitals.

Keywords

Drug utilization Treatment duration Zolpidem Healthcare database 

Notes

Acknowledgements

This study used National Health Insurance Service (NHIS)—National Sample Cohort data (REQ0000006111) made available by the NHIS.

Funding information

This research was supported by Korea-Canada Cooperative Development Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (MSIT) (No.2017K1A3A1A12073341).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Rush CR (1998) Behavioral pharmacology of zolpidem relative to benzodiazepines: a review. Pharmacol Biochem Behav 61:253–269CrossRefGoogle Scholar
  2. 2.
    Darcourt G, Pringuey D, Sallière D, Lavoisy J (1999) The safety and tolerability of zolpidem--an update. J Psychopharmacol 13:81–93.  https://doi.org/10.1177/026988119901300109 CrossRefGoogle Scholar
  3. 3.
    Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L (2003) New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 26:261–282CrossRefGoogle Scholar
  4. 4.
    Holm KJ, Goa KL (2000) Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 59:865–889CrossRefGoogle Scholar
  5. 5.
    Maarek L, Cramer P, Attali P, Coquelin JP, Morselli PL (1992) The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J Int Med Res 20:162–170.  https://doi.org/10.1177/030006059202000208 CrossRefGoogle Scholar
  6. 6.
    Walsh JK, Roth T, Randazzo A et al (2000) Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 23:1087–1096CrossRefGoogle Scholar
  7. 7.
    Dundar Y, Boland A, Strobl J et al (2004) Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technol Assess 8:iii–iix 1–125CrossRefGoogle Scholar
  8. 8.
    Kang D-Y, Park S, Rhee C-W, Kim YJ, Choi NK, Lee J, Park BJ (2012) Zolpidem use and risk of fracture in elderly insomnia patients. J Prev Med Public Health 45:219–226.  https://doi.org/10.3961/jpmph.2012.45.4.219 CrossRefGoogle Scholar
  9. 9.
    Berry SD, Lee Y, Cai S, Dore DD (2013) Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Intern Med 173:754–761.  https://doi.org/10.1001/jamainternmed.2013.3795 CrossRefGoogle Scholar
  10. 10.
    Yang Y-H, Lai J-N, Lee C-H, Wang J-D, Chen P-C (2011) Increased risk of hospitalization related to motor vehicle accidents among people taking zolpidem: a case-crossover study. J Epidemiol 21:37–43CrossRefGoogle Scholar
  11. 11.
    Brodeur MR, Stirling AL (2001) Delirium associated with zolpidem. Ann Pharmacother 35:1562–1564.  https://doi.org/10.1345/aph.10385 CrossRefGoogle Scholar
  12. 12.
    Aragona M (2000) Abuse, dependence, and epileptic seizures after zolpidem withdrawal: review and case report. Clin Neuropharmacol 23:281–283CrossRefGoogle Scholar
  13. 13.
    Cubała WJ, Landowski J (2007) Seizure following sudden zolpidem withdrawal. Prog Neuro-Psychopharmacol Biol Psychiatry 31:539–540.  https://doi.org/10.1016/j.pnpbp.2006.07.009 CrossRefGoogle Scholar
  14. 14.
    Victorri-Vigneau C, Dailly E, Veyrac G, Jolliet P (2007) Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol 64:198–209.  https://doi.org/10.1111/j.1365-2125.2007.02861.x CrossRefGoogle Scholar
  15. 15.
    Hajak G, Müller WE, Wittchen HU, Pittrow D, Kirch W (2003) Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98:1371–1378CrossRefGoogle Scholar
  16. 16.
    Kapil V, Green JL, Le Lait C, Wood DM, Dargan PI (2014) Misuse of benzodiazepines and Z-drugs in the UK. Br J Psychiatry 205:407–408.  https://doi.org/10.1192/bjp.bp.114.149252 CrossRefGoogle Scholar
  17. 17.
    Andersen ABT, Frydenberg M (2011) Long-term use of zopiclone, zolpidem and zaleplon among Danish elderly and the association with sociodemographic factors and use of other drugs. Pharmacoepidemiol Drug Saf 20:378–385.  https://doi.org/10.1002/pds.2104 CrossRefGoogle Scholar
  18. 18.
    Omvik S, Pallesen S, Bjorvatn B, Sivertsen B, Havik OE, Nordhus IH (2010) Patient characteristics and predictors of sleep medication use. Int Clin Psychopharmacol 25:91–100.  https://doi.org/10.1097/YIC.0b013e328334e5e6 CrossRefGoogle Scholar
  19. 19.
    Ohayon MM (2002) Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 6:97–111CrossRefGoogle Scholar
  20. 20.
    Mulvale G, Hurley J (2008) Insurance coverage and the treatment of mental illness: effect on medication and provider use. J Ment Health Policy Econ 11:177–199Google Scholar
  21. 21.
    Bertisch SM, Herzig SJ, Winkelman JW, Buettner C (2014) National use of prescription medications for insomnia: NHANES 1999-2010. Sleep 37:343–349.  https://doi.org/10.5665/sleep.3410 CrossRefGoogle Scholar
  22. 22.
    Lai M-M, Lin C-C, Lin C-C, Liu C-S, Li T-C, Kao C-H (2014) Long-term use of zolpidem increases the risk of major injury: a population-based cohort study. Mayo Clin Proc 89:589–594.  https://doi.org/10.1016/j.mayocp.2014.01.021 CrossRefGoogle Scholar
  23. 23.
    Chen P-L, Lee W-J, Sun W-Z, Oyang Y-J, Fuh J-L (2012) Risk of dementia in patients with insomnia and long-term use of hypnotics: a population-based retrospective cohort study. PLoS One 7:e49113.  https://doi.org/10.1371/journal.pone.0049113 CrossRefGoogle Scholar
  24. 24.
    Hoffmann F, Pfannkuche M, Glaeske G (2008) High usage of zolpidem and zopiclone. Cross-sectional study using claims data. Nervenarzt 79:67–72.  https://doi.org/10.1007/s00115-007-2280-6 CrossRefGoogle Scholar
  25. 25.
    Hsiao F-Y, Hsieh P-H, Gau C-S (2013) Ten-year trend in prescriptions of z-hypnotics among the elderly: a nationwide, cross-sectional study in Taiwan. Journal of Clinical Gerontology and Geriatrics 4:37–41.  https://doi.org/10.1016/j.jcgg.2012.12.001 CrossRefGoogle Scholar
  26. 26.
    Johnsen MT, Wynn R, Bratlid T (2012) Is there a negative impact of winter on mental distress and sleeping problems in the subarctic: the Tromsø study. BMC Psychiatry 12:225.  https://doi.org/10.1186/1471-244X-12-225 CrossRefGoogle Scholar
  27. 27.
    Morin CM, LeBlanc M, Daley M, Gregoire JP, Mérette C (2006) Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med 7:123–130.  https://doi.org/10.1016/j.sleep.2005.08.008 CrossRefGoogle Scholar
  28. 28.
    Ohayon MM, Hong S-C (2002) Prevalence of insomnia and associated factors in South Korea. J Psychosom Res 53:593–600CrossRefGoogle Scholar
  29. 29.
    Hausken AM, Furu K, Skurtveit S, Engeland A, Bramness JG (2009) Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. Eur J Clin Pharmacol 65:295–301.  https://doi.org/10.1007/s00228-008-0565-8 CrossRefGoogle Scholar
  30. 30.
    Kim C Prescription drugs for 300 days? Long term prescriptions that hold patients hostage make patients sick. hankookilbo. Available at: http://www.hankookilbo.com/v/2357613cc8904733b9992e18279dabde. Accessed August 9, 2017
  31. 31.
    Kesselheim AS, Donneyong M, Dal Pan GJ, Zhou EH, Avorn J, Schneeweiss S, Seeger JD (2017) Changes in prescribing and healthcare resource utilization after FDA drug safety communications involving zolpidem-containing medications. Pharmacoepidemiol Drug Saf 26:712–721.  https://doi.org/10.1002/pds.4215 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.School of PharmacySungkyunkwan UniversitySuwonSouth Korea

Personalised recommendations